在糖尿病小鼠中,黑色素的低血糖和肠道微生物群调节作用
Changda Su1, Zhaojie Mao1, Peipei Qi1
1School of Public Health, Shandong Second Medical University, Weifang, China.
Journal of the science of food and agriculture
|November 12, 2024
概括
来自芝麻残留物的黑色素因子通过改善葡萄糖控制和肠道健康,显示出治疗2型糖尿病 (T2DM) 的潜力. 这些化合物激活关键的代谢通路,并对T2DM小鼠的肠道细菌产生积极影响.
科学领域:
- 食品化学 食品化学
- 生物化学 生物化学
- 营养保健品 营养保健品
背景情况:
- 芝麻油的水性提取产生了大量的黑色素.
- 这些芝麻衍生的黑色素的特征和生物活性在很大程度上仍然没有被描述.
研究的目的:
- 从芝麻残留物 (MELs) 中研究黑色素的化学特性和生物活性功能.
- 评估MELs在调节2型糖尿病 (T2DM) 的潜力,体内和体外.
主要方法:
- 使用电子舌头,光和FTIR光谱学对MEL的表征.
- 在体外酶抑制试验 (α-葡萄糖酶,α-氨酶,胰腺脂酶).
- 在T2DM小鼠体内研究,评估代谢参数,肝功能和肠道微生物群组成;西部斑分析以阐明途径.
主要成果:
- MELs是棕色的,具有蛋白质骨架和异芳香结构的宏分子化合物,具有苦味.
- 在体外,MEL抑制了与糖尿病相关的关键酶,并在T2DM小鼠中改善了血糖控制,脂质配置和肝功能.
- MELs调节了IRS-1/PI3K/Akt和AMPK通路,增强了糖解和糖原合成,并有益地改变了肠道微生物群组成 (减少了Firmicutes/Bacteroides比率,增加了乳酸菌).
结论:
- 芝麻衍生的黑色素 (MELs) 在T2DM管理中显示出治疗潜力.
- MELs通过激活IRS-1/PI3K/Akt和AMPK信号通路来调节T2DM.
- MELs可以改善与T2DM相关的肠道微生物群失调.
更多相关视频
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
9.6K
07:35Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
Published on: January 26, 2024
1.3K
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
01:15Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K